When traditional antidepressants haven’t brought the relief you deserve, hope begins with innovation. Spravato® (esketamine) nasal spray is a scientifically advanced, FDA-approved treatment that provides a fresh, powerful approach for adults living with treatment-resistant depression (TRD) — especially for those who have not seen improvement with multiple oral antidepressants.
At McMonigle Neurology Associates, we are proud to offer this cutting-edge option to patients seeking meaningful improvement in mood, energy, and quality of life.
Unlike traditional antidepressants that act primarily on serotonin or other monoamine pathways, Spravato works by targeting NMDA receptors in the brain — part of the glutamate signaling system. This distinct mechanism supports enhanced neuroplasticity, helping the brain adapt and form healthier patterns of emotional regulation. Patients may experience symptom improvement in as little as 24 hours — often far sooner than with conventional treatments.
This rapid action is especially meaningful for adults whose depression has not responded well to standard medications.
One of the most remarkable aspects of Spravato® is its speed of action. In clinical studies, many patients reported improvements in depressive symptoms — including mood, motivation, and energy levels — within the first day of treatment. This rapid response is life-changing for individuals who have been navigating depression for months or years without meaningful relief.
At McMonigle Neurology Associates, we combine medical precision with compassionate support, giving patients the best possible start on their healing journey.
Spravato® has shown effectiveness in:
Increasing response and remission rates for adults with treatment-resistant depression.
Supporting functional improvements, such as better motivation, clearer thinking, and more engagement in daily life.
Helping patients unlock new possibilities for emotional resilience and well-being after traditional treatments have fallen short.
This is not just symptom management — it’s about opening the door to more meaningful days and greater participation in life’s moments.
Spravato®’s approval as a treatment option for adults with TRD reflects a large body of controlled research demonstrating its effectiveness in improving depression symptoms. The fact that the FDA has now approved Spravato® as a standalone therapy — without requiring daily oral antidepressants — underscores its strong clinical value for many patients.
At McMonigle Neurology Associates, we use this evidence as part of a thoughtful, individualized care plan that pairs medical expertise with personal support.
Spravato® treatments are administered in certified healthcare settings, allowing our experienced medical team to provide safe, attentive care throughout each session. While it is delivered under professional supervision, our goal is to make every step comfortable, encouraging, and empowering for our patients.
Our clinicians guide you through the treatment process with:
Personalized care planning
Continuous monitoring for comfort and safety
Supportive follow-up to reinforce progress
You’re never alone in your path toward greater wellness — we walk with you.
For many patients, Spravato® nasal spray means:
Renewed energy and emotional capacity
Restored motivation and focus
A sense of hope that everyday life is worth engaging in again
These are more than clinical outcomes — they are meaningful improvements in how patients experience their lives.
Spravato® is designed specifically for adults with treatment-resistant depression, meaning those who have tried at least two antidepressants without sufficient improvement. Our team at McMonigle Neurology Associates will thoughtfully assess your history, symptoms, and goals to determine whether Spravato® may be a valuable part of your individualized care plan.
